MSC-derived exosomes

Class

Mesenchymal stem cell-derived extracellular vesicle therapy

Exosomes are small membrane-bound vesicles, roughly 30 to 150 nanometers in diameter, that cells release to carry proteins, lipids, and RNA to other cells, a process called paracrine signaling. Mesenchymal stem cells (MSCs), multipotent cells found in bone marrow, umbilical cord, and adipose tissue, have long been studied for their ability to dampen inflammation and support tissue repair. Research has increasingly shown that much of this benefit arises not from MSCs physically engrafting into damaged tissue but from the biomolecules they secrete. MSC-derived exosomes isolate and concentrate this secreted activity into a cell-free biologic product. Because they lack a nucleus and cannot divide, they avoid the engraftment and tumor-forming risks associated with transplanting living cells, while still delivering cargo capable of influencing immune cell behavior, reducing inflammatory signaling, and promoting blood vessel formation and tissue regeneration. This mechanism is of broad interest across conditions marked by excess inflammation and tissue injury, including inflammatory and autoimmune disorders, acute lung injury, chronic wounds, and ischemic or degenerative disease. As a therapeutic class, MSC exosome products occupy a middle ground between conventional protein biologics and live cell therapy, aiming for more standardized manufacturing while preserving the broad, multifactorial signaling that whole cells provide.